The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists
Novartis' experimental heart drug Pelacarsen has failed a pivotal study, surprising both the company and cardiologists.
Evidence dossier
Intelligence passport
Measured timeline
- Detected The first matching coverage entered the Archynetys cluster.
- Evidence threshold reached The story had enough independent coverage for an explanatory brief.
- Latest coverage observed Most recent article currently attached to this story cluster.
- Peak measured velocity The recorded velocity reached 18.
Source diversity sample: Fierce Biotech · WSJ · bloomberg.com · Reuters · STAT · The New York Times.
How this dossier is built: methodology · AI policy · corrections.
Who reported it (6)
- Novartis Lp(a) drug fails to lower cardiovascular risk in closely watched ph. 3 trial Fierce Biotech · 3h ago
- Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint WSJ · 3h ago
- Novartis Drug Fails Key Test of New Approach to Heart Disease bloomberg.com · 3h ago
- Novartis, Ionis' experimental heart drug misses key goal in closely watched trial Reuters · 3h ago
- Novartis’ experimental cardiovascular drug fails a pivotal study STAT · 3h ago
- The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists The New York Times · 3h ago
What happened
One experimental heart drug has failed a pivotal study. Pelacarsen, developed by Novartis and Ionis, did not meet its primary endpoint in a closely watched trial. The drug was designed to target a new approach to heart disease, specifically by lowering lipoprotein(a), a known risk factor for cardiovascular events. The failure of Pelacarsen comes as a shock to Novartis and the cardiology community.
The New York Times notes that cardiologists had high hopes for the drug, given its unique mechanism of action. The drug's failure raises questions about the future of this approach to heart disease treatment. Novartis and Ionis will need to reassess their strategies moving forward. The next steps for Novartis and Ionis are unclear.
The companies will likely need to analyze the trial data to understand why Pelacarsen failed to meet its primary endpoint. Depending on the findings, they may consider further research or abandon this particular approach. The broader implications for heart disease treatment and research will also be closely watched.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Questions people are asking
What is Pelacarsen?
Pelacarsen is an experimental heart drug developed by Novartis and Ionis. It is designed to lower lipoprotein(a), a risk factor for cardiovascular events.
Why is the failure of Pelacarsen significant?
The failure is significant because it represents a setback in the development of a new approach to heart disease treatment. The drug had generated considerable interest and hope within the cardiology community.
What happens next for Novartis and Ionis?
Novartis and Ionis will need to analyze the trial data to understand the reasons behind Pelacarsen's failure. They may consider further research or abandon this particular approach based on their findings.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Topics
Related trends
Novartis inks $3.2B subcutaneous delivery deal with Alteogen
Novartis's $3.2B deal with Alteogen is a surprise move that could reshape the subcutaneous drug delivery market.
New guidelines recommend all patients with heart disease are tested for kidney disease
New clinical guidelines now recommend universal kidney disease screening for all patients diagnosed with heart disease.
Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up
Two positive Phase III results for an oral multiple sclerosis drug have pushed Novartis forward in a competitive pharmaceutical market.
Boston Scientific discontinues angiographic catheters
Boston Scientific removes angiographic and imaging catheters from the market following high-severity device recalls and safety alerts.
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis’s Rhapsido clears two Phase III hurdles, sending its stock soaring.
Artificial sweetener linked to higher risk of cardiovascular events
A widely used sweetener found in food, beverages, and gum is now linked to a higher risk of heart attacks and strokes.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.